Pfizer Inc PFE

$28.28 +0.46 (1.65%)

Valuation

Market cap
159,590,864,000
Revenue TTM
$62,579,000,000
Net income TTM
$7,771,000,000
PE ratio
9.02
Forward PE
9.24
Profit margin
12.42%
Debt to equity
0.74

Trading

Volume
23,184,521
Avg volume
35,740,172
Day's range
$27.59 – $28.28
Shares out
5,699,674,000
Stochastic %K
38%
Beta
0.32
Analysts
Sell
Price target
$29.06

Price

Company profile

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under...

Show more

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Industry
Drug Manufacturers - General
Sector
Healthcare
Phone
212 733 2323
Website
https://www.pfizer.com
Address
66 Hudson Boulevard East, New York, United States

Latest news

Stocktwits

BarkingPuppy Oct 9, 7:01 PM
$ELTP $BTC.X $SPCX $PFE One Hour to go. Lets get this to .30 before the close. I know big players are moving in. Get in before they do and the news hits. Buying Big time!!!!
0 replies
ProTraderColin Oct 9, 6:48 PM
$PFE thank god it rebounded. Exited my calls for a small win.
0 replies
cubie Oct 9, 5:51 PM
$MRNA $BNTX $MRK $PFE $NVAX got pump with cancer stonks🤔
2 replies
Gj64 Oct 9, 4:57 PM
$PFE https://finance.yahoo.com/markets/stocks/articles/investors-heavily-search-pfizer-inc-120003137.html
0 replies
Stoxpo Oct 9, 4:46 PM
Moderna Stock Surges as New Cancer Vaccine Initiative Fuels Investor Optimism https://stoxpo.com/index.php/2026/10/09/moderna-stock-surges-as-new-cancer-vaccine-initiative-fuels-investor-optimism/ $MRNA $PFE $BNTX $SPY $XBI
0 replies
zustrelaax Oct 9, 4:21 PM
$MRNA , $NVAX $PFE move is pending can we get 29 today ?
1 replies
STOCKPICKERTRADER Oct 9, 3:53 PM
$PFE upgrades and price target increases just keep coming.... finally DBS Bank Adjusts Price Target on Pfizer to $35 From $30 MT NEWSWIRES Oct-09-2026 11:33 a.m. ET 11:33 AM EDT, 10/09/2026 (MT Newswires) -- Pfizer (PFE) has an average rating of hold and mean price target of $28.99, according to analysts polled by FactSet. (MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www.mtnewswires.com/contact-us)
1 replies
jackofalltrade Oct 9, 3:41 PM
DBS Bank adjust price target on $PFE Pfizer from $30 to $35.
0 replies